Intellia Therapeutics (NTLA) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Intellia Therapeutics (NTLA) is Neutral.

The composite score behind that read is -0.03, weighing +0.20 of bullish evidence against -0.30 bearish.

Intellia Therapeutics last closed at $13.07, +3.73% on the session.

Against the IVW growth benchmark the position is +2.93% over the forecast window.

The read is built from 15 underlying insights — 3 bullish and 12 bearish.

Agreement across those insights is 80%.

20 graded predictions for NTLA so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Intellia Therapeutics in the 17th percentile on return on equity, where 100 is best.

Intellia Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $1.77B.

StockMap tracks Intellia Therapeutics as the 103rd largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Intellia Therapeutics ranks 132nd of 381 in the group, against a group median of -0.08.